Hong Kong Exchanges and Clearing Ltd $0388.HK is taking strategic steps to enhance its standing as a global financial hub. In a bid to attract cross-border capital flows and new listings, HKEX is actively courting companies from Southeast Asia and the Middle East—especially those seeking secondary listings. CEO Bonnie Chan recently outlined this direction, positioning Hong Kong as a vital gateway between East and West.
Jiangsu Hengrui Pharmaceuticals Co. $600276.SS, a prominent Chinese drug developer specializing in oncology and cardiovascular innovations, executed its secondary listing in Hong Kong by setting the share price at the upper limit. The company raised 9.9 billion Hong Kong dollars (approximately USD 1.3 billion), a capital infusion underlining the significant appetite for high-quality Chinese healthcare assets on the Hong Kong Stock Exchange.
Ant Group, the fintech arm of Chinese e-commerce powerhouse Alibaba Group $BABA, is moving ahead with plans to list its overseas division, Ant International, on the Hong Kong Stock Exchange. This move is a strategic effort to boost its global presence and further cement its role in digital financial services beyond China.
On Tuesday, Chinese technology giant Xiaomi Corp announced that it secured USD 5.5 billion through an equity placement, marking a significant step in its ambitious plan to venture further into electric vehicle production. Renowned as the world’s third-largest smartphone manufacturer, Xiaomi successfully concluded the deal on the Hong Kong Stock Exchange, reinforcing its strategic commitment to innovation and market expansion.
Following a leadership shake-up and increased state support, shares of China Vanke surged on the Hong Kong Stock Exchange. The state intervention aims to mitigate liquidity risks and ensure the company's steady development amidst economic changes.
